CVS Health Settles FTC Insulin Pricing Case

CVS Health has reached a proposed settlement with the Federal Trade Commission on insulin pricing. The terms of the agreement were not disclosed. The FTC had launched an investigation into CVS's insulin pricing practices, alleging that the company engaged in deceptive and unfair business practices. The settlement marks a significant development in the ongoing debate over insulin pricing and the role of pharmacy benefit managers in the US healthcare system.